SecBot SecBot
SECBOTREPLAY Home › Report › ANVS

ANVS · Annovis Bio reported financial results for 2025 alongside clinical…

Annovis Bio Inc. · PRESS-RELEASE filed Mar 16, 2026 at 07:30 ET

At the news

MIXEDIMPACT 6/10

PRESS-RELEASE filed Mar 16, 2026 at 07:30 ET

Annovis Bio reported financial results for 2025 alongside clinical progress updates, including initiation of a pivotal Phase 3 trial in Alzheimer's disease and an open-label extension study in Parkinson's disease. The company showed improved net loss per share despite higher R&D spending, with cash of $19.5 million enabling operations into Q3 2026.

  • Initiated pivotal Phase 3 trial in early Alzheimer's disease (NCT06709014) with 65% enrollment achieved by March 2026 across 83 U.S. sites.
  • Launched open-label extension (OLE) study in Parkinson's disease (NCT07284784) in January 2026 to assess long-term safety and efficacy over 36 months.
  • Received positive DSMB safety review for buntanetap at 6 months in the AD trial, supporting continuation without modifications.
  • Met with FDA in January 2026 to discuss a potential Phase 3 trial in Parkinson's disease dementia (PDD), receiving a positive recommendation to proceed.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access